Future human clinical trials with ATR-002 may provide additional data to help determine the safety and efficacy of MEK1/2 inhibitor compounds during human respiratory infections and could serve as a foundation for evaluating the safety for translational application in PwCF. This evidence concerns the gene MAP2K1 and respiratory tract infectious disorder.